Locally advanced or metastatic HER2-expressing cancers

Clinical trials for Locally advanced or metastatic HER2-expressing cancers explained in plain language.

Never miss a new study

Get alerted when new Locally advanced or metastatic HER2-expressing cancers trials appear

Sign up with your email to follow new studies for Locally advanced or metastatic HER2-expressing cancers, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo targets Hard-to-Treat HER2 cancers

Disease control Recruiting now

This early-stage trial is testing a new drug called VIR-5818, alone or combined with the immunotherapy pembrolizumab, in people with advanced HER2-expressing cancers that have not responded to standard treatments. The study will first find the safest dose, then expand to see if t…

Matched conditions: LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS

Phase 1/2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control

Last updated Aug 21, 2026 00:00 UTC

Locally advanced or metastatic HER2-expressing cancers

Get alerted when new Locally advanced or metastatic HER2-expressing cancers trials appear

New drug combo targets Hard-to-Treat HER2 cancers